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Abstract
The peptide somatostatin (SRIF) has important physiological effects, mostly inhibitory, which have formed the basis for the clinical use of
SRIF compounds. SRIF binding to its 5 guanine nucleotide-binding proteins-coupled receptors leads to the modulation of multiple transduction
pathways. However, our current understanding of signaling exerted by receptors endogenously expressed in different cells/tissues reflects a rather
complicated picture. On the other hand, the complexity of SRIF receptor signaling in pathologies, including pituitary and nervous system diseases,
may be studied not only as alternative intervention points for the modulation of SRIF function but also to exploit new chemical space for drug-like
molecules.
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2+ concentration; Aβ, amyloid-β peptide; AD, Alzheimer’s disease; CaMKII, Ca2+/calmodulin-dependent protein kinase II;
cdk, cyclin-dependent protein kinase; DEP/PTP, density-enhanced protein-tyrosine phosphatase; ERK, extracellular signal-regulated protein kinases; G proteins,
guanine nucleotide-binding proteins; GH, growth hormone; GIP, GPCR-interacting proteins; GPCR, G protein-coupled receptors; GRK, GPCR protein kinases;
GSK, glycogen synthase protein kinase; IKK, inhibitor κB protein kinase; ILK, integrin-linked protein kinase; IP3, inositol trisphosphate; MAP kinases, mitogen-
activated protein kinases; PDK, phosphoinositide-dependent kinase; PI3 kinase, phosphatidylinositol 3 protein kinase; PKA, cAMP-dependent protein kinase; PKC,
phospholipase C-dependent protein kinase; PKG, cGMP-dependent protein kinase; PP, serine/threonine phosphatases; RGS, regulators of G-protein signaling; r-PTP,
receptor-like tyrosine phosphatase; SAPK/JNK, stress-activated protein kinase/c-Jun NH2-terminal protein kinase; SHP, SH2 domain-containing cytosolic tyrosine
phosphatase; SRIF, somatostatin or somatotropin release inhibiting factor; sst1-5, somatostatin receptor 1 to 5.
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